161 related articles for article (PubMed ID: 37388210)
1. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
2. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract][Full Text] [Related]
3. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
4. Prediction of thyroid hormone supplementation after thyroid lobectomy.
Lee DY; Seok J; Jeong WJ; Ahn SH
J Surg Res; 2015 Jan; 193(1):273-8. PubMed ID: 25088372
[TBL] [Abstract][Full Text] [Related]
5. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
6. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
Xia Q; Dong S; Bian PD; Wang J; Li CJ
Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
[TBL] [Abstract][Full Text] [Related]
7. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study.
Papaleontiou M; Chen DW; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Haymart MR
Thyroid; 2021 Sep; 31(9):1383-1390. PubMed ID: 33779292
[No Abstract] [Full Text] [Related]
9. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
10. Thyroid function related symptoms during levothyroxine monotherapy in athyreotic patients.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Kudo T; Nishihara E; Kihara M; Ito Y; Miya A; Fukata S; Nishikawa M; Nakamura H
Endocr J; 2019 Nov; 66(11):953-960. PubMed ID: 31270299
[TBL] [Abstract][Full Text] [Related]
11. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
12. Combined prognostic value of preoperative serum thyrotrophin and thyroid hormone concentration in papillary thyroid cancer.
Liu Y; Huang Y; Mo G; Zhou T; Hou Q; Shi C; Yu J; Lv Y
J Clin Lab Anal; 2022 Jul; 36(7):e24503. PubMed ID: 35666615
[TBL] [Abstract][Full Text] [Related]
13. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
14. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I; Fujimoto Y
Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
[TBL] [Abstract][Full Text] [Related]
15. Biochemical Markers Reflecting Thyroid Function in Athyreotic Patients on Levothyroxine Monotherapy.
Ito M; Miyauchi A; Hisakado M; Yoshioka W; Ide A; Kudo T; Nishihara E; Kihara M; Ito Y; Kobayashi K; Miya A; Fukata S; Nishikawa M; Nakamura H; Amino N
Thyroid; 2017 Apr; 27(4):484-490. PubMed ID: 28056660
[TBL] [Abstract][Full Text] [Related]
16. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
17. Inverse Relationship of BMI to TSH and Risk of Papillary Thyroid Cancer in Surgical Patients.
Handelsman RS; Alvarez AL; Picado O; Farrá JC; Lew JI
J Surg Res; 2019 Dec; 244():96-101. PubMed ID: 31280000
[TBL] [Abstract][Full Text] [Related]
18. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.
Jonklaas J; Nsouli-Maktabi H; Soldin SJ
Thyroid; 2008 Sep; 18(9):943-52. PubMed ID: 18788918
[TBL] [Abstract][Full Text] [Related]
19. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients.
Bartalena L; Martino E; Pacchiarotti A; Grasso L; Aghini-Lombardi F; Buratti L; Bambini G; Breccia M; Pinchera A
J Clin Endocrinol Metab; 1987 Apr; 64(4):849-55. PubMed ID: 3818906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
